Technology evaluation: StealthVector (HIV) Enzo

Current Opinion in Molecular Therapeutics

Volumn 1, Issue 5, 1999, Pages 651-657

  Günzburg, Walter ^a   Mhashilkar, Abner M ^b   Hindi, Mustafa ^b  

^a Institute of Molecular Virology   (Germany)

^b Introgen Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; GENE EXPRESSION; GENE THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PHASE 1 CLINICAL TRIAL; REVIEW; VIROGENESIS; VIRUS REPLICATION;

EID: 2442750410     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Gibaldi M: Human Gene Therapy. Pharmacotherapy (1993) 13:79-87.
2. Sarver N, Cantin PS, Chang PS, Zala JA, Ladne PA, Stephen PA, Rossi JJ: Ribozymes as potential HIV-1 therapeutic agents. Science (1990) 247:1222-1225.
3. Enzo Biochem Inc. Enzo Biochem reports preclinical findings at International AIDS conference. Press Release July 10 1996.
4. Haubrich R, McCutchan JA, Holdredge R, Heiner L, Merritt J, Merchant B: An open label, phase I/II clinical trial to evaluate the safety and biological activity of HIV-IT (V) (HIV-1IIIBenv/rev retroviral vector) in HIV-1-infected subjects. Hum Gene Ther (1995) 6(7):941-955.
5. Bauer G, Valdez P, Keams K, Bahner I, Sui F, Zaia JA, Kohn DB: Inhibition of human immunodeficiency virus-1 (HIV-1) replication after transaction of granulocyte colony-stimulating factor-mobilized CD34+ cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes. Blood (1997) 89(7):2259-2267.
6. Chatterjee S, Johnson PR, Wong KK Jr: Dual target inhibition of HIV-1 in vitro by means of an adeno-associated virus anti-sense vector. Science (1992) 258:1485-1489.
7. Malim MH, Bohnlein S, Hauber J, Cullen BR: Functional dissection of HIV-1 rev trans activator derivation of transdominant represser of Rev function. Cell (1989) 58:205-214.
8. Veres G, Junker U, Baker J, Barske C, Kalfoglou C, lives H, Escaich S, Kaneshima H, Bohnlein E. Comparative Analyses of Intracellularly Expressed antisense RNAs as inhibitors of human Immunodeficiency virus type 1 replication. J Virol (1998) 72:1894-1901.
9. Enzo Biochem Inc. Enzo scientist presents paper at Geneva AIDS conference. Studies show high level of protection against HIV. Press Release July 2 1998.
10. Enzo Biochem Inc. Enzo Biochem initiates phase I human clinical trials of novel genetic medicine for treatment of HIV-1 infection. Press Release July 3 1998.
11. Liu D, Donegan J, Nuovo G, Mitra D, Laurence J: Stable human Immunodeficiency virus type 1 (HIV-1) resistance in transformed CD4+ monocytic cells, treated with multi-targeting HIV-1 antisense sequences incorporated into U1 snRNA. J Virol (1997) 71:4079-4085.
12. Drug Development Pipeline (1998) 3:371.
13. Robertson ES: Technology Evaluation: DISC. Curr Opin Mol Ther (1999) 1:112-115.
14. Marasco WA, Haseltine WA, Chen S-Y: Design, intracellular expression and activity of a human anti human immunodeficiency virus type 1 gp120 single chain antibody. Proc Natl Acad Sci USA (1993) 90:7889-7893.
15. Richardson JH, Marasco WA: Intracellular antibodies: Development and therapeutic potential. Trends Biotechnol (1995) 13:306-310.
16. Mhashilkar AM, Bagley J, Chen S-Y, Szilvay AM, Marasco WA: Inhibition of HIV-1 Tat mediated LTR transactivation and HIV infection by anti Tat single chain antibodies. EMBO J (1995) 14:1542-1551.
17. Maciejewski JP, Weichold FF, Young NS, Cara A, Zella D, Reitz MS, Gallo RC: Intracellular expression of antibody fragments directed against HIV reverse transcriptase prevents HIV infection in vitro. Nature Med (1995) 1:667-673.
18. Trono D, Feinbrg MB, Baltimore D: HIV-1 gag mutants can dominantly interfere with the replication of the wild type virus. Cell (1989) 59:113-120.
19. Green G, Ishino M, Loweinstein PM: Mutational analysis of HIV-1 of HIV-1 tat minimal domain peptides: Identification of transdominant mutants that suppress HIV-1 LTR driven gene expression. Cell (1989) 58:215-223.
20. Anguilar-Cordova E, Chinen J, Donehower LA, Harper JW, Rice AP, Butel JS, Belmont JW: Inhibition of HIV-1 by double transdominant fusion gene. Gene Ther (1995) 2:181-186.
21. Gilboa E, Smith C: Gene Therapy for infectious diseases: The AIDS model. Trends Genetics (1994) 10:139-144.
22. Hnatowich DJ: Antisense and nuclear medicine. J Nucl Med (1999) 40:693-703.
23. Lo KMS, Biasola MA, Dehni G, Palu G, Haseltine WA: Inhibition of replication of HIV-1 by retroviral vectors expressing tat antisense and anti-Tat ribozyme RNA. J Virol (1992) 190:176-183.
24. Bevec D, Volc-Platzer B, Zimmermann K, Dobrovnik M, Hauber J, Veres G, Bohnlein E: Constitutive expression of chimeric neo-Rev-response element transcripts suppresses HIV-1 replication in human CD4+ T-lymphocytes. Hum Gene Ther (1994) 5:193-201.
25. Marasco WA, Chen S-Y, Richardson JH, Ramstedt U, Jones SD: Clinical protocol: Intracellular antibodies against HIV-1 envelope protein for AIDS gene therapy. Human Gene Ther (1998) 9:1627-1642.
26. Yu M, Ojwang J, Yamada O, Hampel A, Rappaport J, Looney D, Wong-Staal FA: A hair-pin ribozyme inhibits expression of diverse strains of HIV-1. P roc Natl Acad Sci USA (1993) 90:6340-6344.
27. Mhashilkar AM, Biswas DK, LaVecchio J, Pardee AB, Marasco WA: Inhibition of human immunodeficiency virus type 1 replication in vitro by a novel combination of anti-Tat single-chain intrabodies and NF-kappa B antagonists. J Virol (1997)71(9):6486-6494.
28. Lee SW, Gallardo HF, Gilboa E, Smith C: Inhibition of human immunodeficiency virus type 1 in human T-cells by a potent Rev response element decoy consisting of the 13-nucleotide minimal Rev-binding domain. J Virol (1994) 68(12):8254-8264.
29. Galpin JA, Casciato DA, Richards SB: A phase I clinical trial to evaluate the safety and biological activity of HIV-IT (TAF) (HIV-1IIIBenv-transduced, autologous fibroblasts) in asymptomatic HIV-1 infected subjects. Hum Gene Ther (1994) 5(8):997-1017.
30. Chinin J, Aguilar CE, Ng TD, Lewis DE, Belmont JW: Protection of primary human T cells from HIV infection by Trev: a transdominant fusion gene. Hum Gene Ther (1997) 8:861-868.
31. Nabel GJ, Fox BA, Post L, Thompson CB, Woffendin C: A molecular genetic intervention for AIDS - effects of a transdominant negative form of Rev. Hum Gene Ther (1994) 5:79-92.
32. Woffendin C, Ranga U, Yang Z, Nabel GJ: Expression of a protective gene-prolongs survival of T cells in human immunodeficiency virus-infected patients. Proc Natl Acad Sci USA (1996) 93:2889-2894.
33. Ranga U, Woffendin C, Verma S, Xu L, June CH, Bishop JK, Nabel GJ: Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals. Proc Natl Acad Sci USA (1998) 95:1201-1206.
34. Poznansky MC, Foxall R, Mhashikar A, Coker R, Jones S, Ramstedt U, Marasco W: Inhibition of human immunodeficiency virus replication and growth advantage of CD4+ T cells from HIV-infected individuals that express intracellular antibodies against HIV-1 gp120 or Tat Hum Gene Ther (1998) 9:487-496.
35. Keams K, Bahner I, Bauer G, Wei SF, Bauer P, Wheeler S, Woods L, Miller R, Casciato D, Galpin J, Church J, Kohn DB: Suitability of bone marrow from HIV-1-infected donors for retrovirus-mediated gene transfer. Hum Gene Ther (1997) 8(3):301-311.
36. Maniatis T, Reed R: The role of small ribonucleoprotein particles in pre-mRNA splicing. Nature (1987) 325:673-678.
37. Chen JD, Chang Q, Chang AG, Marasco WA: Intra- and extracellular immunization against HIV-1 infection with lymphocytes transduced with an AAV vector expressing a human anti-gp120 antibody. Hum Gene Ther (1996) 7:1515-1525.
38. Mhashilkar AM, LaVecchio J, Eberhardt B, Porter-Brooks J, Boisot S, Dove JH, Pumphrey C, Li X, Weissmahr RN, Ring DB, Ramstadt U, Marasco WA: Inhibition of human Immunodeficiency virus type 1 replication in vitro in acutely and persistently infected human CD4+ mononuclear cells expressing murine and humanized anti-HIV type 1 tat single-chain variable fragment intrabodies. Hum Gene Ther (1999) 10:1453-1467.
39. Walker RE: A phase I/II pilot study of the safety of the adoptive transfer of syngeneic gene-modified cytotoxic T lymphocytes in HIV-infected identical twins. Hum Gene Ther (1996) 7:367-400.
40. Chan SY, Louie MC, Piccotti JR, Iyer G, Ling X, Yang ZY, Nabel GJ, Bishop DK: Genetic vaccination-induced immune responses to the human immunodeficiency virus protein Rev: Emergence of the interleukin 2-producing helper T-lymphocyte. Hum Gene Ther (1998) 9(15):2187-2196.
41. Morgan RA, Walker R: Gene therapy for AIDS using retroviral mediated gene transfer to deliver HIV-1 antisense TAR and transdominant Rev protein genes to syngeneic lymphocytes in HIV-1 infected identical twins. Hum Gene Ther (1996) 7(10):1281-1306.
42. Greenberg P, Gilbert M, Nelson B, Riddell S: Adoptive therapy of infectious diseases in immunocompromised hosts by adoptive transfer of gene modified T-cell clones; cytomegalovirus and HIV virus infection gene therapy by recombinant T-lymphocyte transfer. Cancer Gene Ther (1994) 1(2):144-145.
43. Morgan RA, Bunnell B, Walker R, Lane C, Blaese RM: An AIDS gene therapy trial in HIV-1 discordant identical twins; recombinant retrovirus-mediated TAR and Rev gene transfer to T-lymphocytes for HIV virus-1 infection gene therapy; phase I/II clinical trial. In vitro (1997) 33(3):V-3.
44. Annonymous: OECD Ottawa '95. Workshop on Gene Delivery Systems. Ottawa, Canada, 28-30 June 1995. Gene Ther (1995) 2(8):555-600.
45. Laube LS, Burrascano M, Dejesus CE, Howard BD, Johnson MA, Lee WT, Lynn AE, Peters G, Ronlov GS, Townsend KS, et al: Cytotoxic T lymphocyte and antibody responses generated in rhesus monkeys immunized with retroviral vector-transduced fibroblasts expressing human immunodeficiency virus type-1 IIIB ENV/REV proteins. Hum Gene Ther (1994) 5(7):853-862.
46. Kohn DB, Bauer G, Rice CR, Rothschild JC, Carbonaro DA, Valdez P, Hao QI, Zhou C, Bahner I, Keams K, Brody K, Fox S, Haden E, Wilson K, Salata C, Dolan C, Wetter C, Aguilar-Cordova E, Church J: A clinical trial of retroviral-mediated transfer of a rev-responsive element decoy gene into CD34(+) cells from the bone marrow of human immunodeficiency virus-1-infected children. Blood (1999) 94(1):368-371.